However, a disruption in this process, either by inhibited BAs synthesis or reduced BSEP activity (stemming from suppressed hepatic FXR-small heterodimer partner (SHP) axis signaling), exacerbates NAFLD [14,15,16]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.